GlassScriptPhysician profile
Gloria R Brun
NPI 1417088154
$10,043.98
in general payments reported to CMS, 2019-2025
30 companies · $2,600 in 2025
The $2,600 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $925 · 2021: $1,404 · 2022: $1,299 · 2023: $1,745 · 2024: $1,394 · 2025: $2,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,707 · Education: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,706.69 |
| Education | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,485.45 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,442.37 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $973.26 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $887.12 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Vanda Pharmaceuticals INC. | $642.32 | 2020-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $623.54 | 2021-2025 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $428.80 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $414.16 | 2019-2024 | Jornay Pm |
| Corium, LLC | $388.82 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $325.83 | 2019-2025 | Ingrezza |
| Tris Pharma INC | $286.69 | 2019-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $274.76 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $256.79 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $255.25 | 2019-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $225.62 | 2022-2025 | Quviviq, Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $206.24 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Noven Therapeutics, LLC | $135.41 | 2023-2025 | Xelstrym, Secuado |
| Eisai INC. | $126.75 | 2020-2022 | |
| Adlon Therapeutics L.P. | $124.03 | 2019-2021 | |
| Almatica Pharma LLC | $114.13 | 2021-2025 | Loreev Xr |
| Allergan, INC. | $83.19 | 2019-2020 | |
| Lundbeck LLC | $79.98 | 2022 | |
| Avanir Pharmaceuticals, INC. | $72.38 | 2021-2022 | |
| Owp Pharmaceuticals, INC. | $58.95 | 2022-2024 | Subvenite |
| Collegium Pharmaceutical, INC. | $30.62 | 2025 | Jornay Pm |
| Indivior INC. | $26.50 | 2024 | Perseris |
| Bausch Health US, LLC | $25.17 | 2022 | |
| Avion Pharmaceuticals | $20.22 | 2023 | Methylphenidate Hydrochloride |
| Sunovion Pharmaceuticals INC. | $15.56 | 2020 | |
| Merck Sharp & Dohme LLC | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Brun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.